Blood Tests May be the Future for Early Alzheimer’s Detection
source: shutterstock.com

Blood Tests May be the Future for Early Alzheimer’s Detection

It is estimated that over six million people in the U.S. have Alzheimer’s disease plus millions of other people throughout the world. Alzheimer’s is the most common type of dementia.…

Continue Reading Blood Tests May be the Future for Early Alzheimer’s Detection
Study: 77% of Pregnancies Result in Live Births After Stem Cell Transplant
source: shutterstock.com

Study: 77% of Pregnancies Result in Live Births After Stem Cell Transplant

Women who undergo allogeneic hematopoietic cell transplantation (alloHCT) face significant treatment-related challenges regarding fertility. However, science seems to be overcoming many treatment-related fertility challenges after alloHCT and successful pregnancies are…

Continue Reading Study: 77% of Pregnancies Result in Live Births After Stem Cell Transplant
Proof-of-Concept Trial Suggests That Tezepelumab (TEZSPIRE) Could Play a Role in Treating COPD
source: shutterstock.com

Proof-of-Concept Trial Suggests That Tezepelumab (TEZSPIRE) Could Play a Role in Treating COPD

The COURSE Phase IIa clinical trial was conducted to evaluate tezepelumab (marketed as TEZSPIRE) in people living with chronic obstructive pulmonary disease (COPD) that had a wide range of blood…

Continue Reading Proof-of-Concept Trial Suggests That Tezepelumab (TEZSPIRE) Could Play a Role in Treating COPD
Why Dr. Fiorentino Believes in a Promising Treatment Future for Dermatomyositis
https://unsplash.com/photos/tWTFjznQlBA

Why Dr. Fiorentino Believes in a Promising Treatment Future for Dermatomyositis

In some cases, dermatomyositis can be difficult to treat. A variety of treatment options are available, from corticosteroids and immunosuppressants to antimalarials, colchicine, alendronate, and warfarin. But this rare condition…

Continue Reading Why Dr. Fiorentino Believes in a Promising Treatment Future for Dermatomyositis
Positive Results from the Phase 3 Trial of ANX005 in Guillain-Barré Syndrome
source: shutterstock.com

Positive Results from the Phase 3 Trial of ANX005 in Guillain-Barré Syndrome

The long-awaited positive results of Annexon Inc.’s Phase 3 trial investigating ANX005 for Guillain-Barré syndrome (GBS) was presented at the PNS 2024 Annual Meeting. Several leading global GBS experts spoke…

Continue Reading Positive Results from the Phase 3 Trial of ANX005 in Guillain-Barré Syndrome
These Nonprofits Just Shelled Out $5.2 Million to Fund An Experimental Parkinson’s Drug
source: shutterstock.com

These Nonprofits Just Shelled Out $5.2 Million to Fund An Experimental Parkinson’s Drug

According to a story from PR Newswire, the biotech company Mission Therapeutics was just awarded $5.2 million in funding to support MTX325, the company's investigational Parkinson's disease therapy. Intended to…

Continue Reading These Nonprofits Just Shelled Out $5.2 Million to Fund An Experimental Parkinson’s Drug
Phase 2 Obesity Clinical Trial from Palatin Set to Begin
source: shutterstock.com

Phase 2 Obesity Clinical Trial from Palatin Set to Begin

According to a story from drugs.com, the biopharmaceutical company Palatin Technologies, Inc., which is specializing in the development of therapies that interact with the melanocortin receptor system, recently announced the…

Continue Reading Phase 2 Obesity Clinical Trial from Palatin Set to Begin
Long COVID: What Have We Learned?
source: shutterstock.com

Long COVID: What Have We Learned?

Individuals who appear to have Long COVID may exhibit a variety of symptoms lasting weeks or even years. The latest estimates are that about 10-20% of people infected with SARS-CoV-2…

Continue Reading Long COVID: What Have We Learned?
Japanese Scientists Reversed Signs of Alzheimer’s by Restoring Synapse Function in Mouse Model
source: shutterstock.com

Japanese Scientists Reversed Signs of Alzheimer’s by Restoring Synapse Function in Mouse Model

A team of scientists from Japan appear to have pioneered a method for reversing synapse damage in an Alzheimer's disease mouse model. Although encouraging, the theory must be tested in…

Continue Reading Japanese Scientists Reversed Signs of Alzheimer’s by Restoring Synapse Function in Mouse Model
This Drug Could Prevent PAH in People with Scleroderma
source: shutterstock.com

This Drug Could Prevent PAH in People with Scleroderma

According to a story from Scleroderma News, findings from the recent Phase 2 EDITA clinical trial suggested that ambrisentan (marketed as Letairis), which is approved to treat pulmonary arterial hypertension…

Continue Reading This Drug Could Prevent PAH in People with Scleroderma
Higher Sugar Intake Boosts Risk of Liver Fibrosis in Latino Teens
source: shutterstock.com

Higher Sugar Intake Boosts Risk of Liver Fibrosis in Latino Teens

Professor Michael Goran was referring to research data that was presented at the annual 2023 conference of the Hepatology, Gastroenterology, and Nutrition Society of North America when he stressed that…

Continue Reading Higher Sugar Intake Boosts Risk of Liver Fibrosis in Latino Teens
Physicians Identify Poor Disease Management in Patients with IBD
source: shutterstock.com

Physicians Identify Poor Disease Management in Patients with IBD

Effective disease management in inflammatory bowel disease (IBD), which encompasses Crohn’s disease and ulcerative colitis, is incredibly important. Managing your condition helps you maintain a better quality-of-life, reduces uncomfortable or…

Continue Reading Physicians Identify Poor Disease Management in Patients with IBD
Encouraging Results from a Phase 2 Study of IL-2 to Treat Alzheimer’s Patients
kkolosov / Pixabay

Encouraging Results from a Phase 2 Study of IL-2 to Treat Alzheimer’s Patients

BioSpace recently published a press release discussing the interim results highlighting a Coya Therapeutics’ study. The study evaluates the safety, tolerability, and biological activity of LD IL-2 in 38 patients…

Continue Reading Encouraging Results from a Phase 2 Study of IL-2 to Treat Alzheimer’s Patients
Suicidal Bipolar Depression: Clinical Trial Results of NRX-101 Found Superior Safety and Similar Efficacy Compared to Lurasidone
source: pixabay.com

Suicidal Bipolar Depression: Clinical Trial Results of NRX-101 Found Superior Safety and Similar Efficacy Compared to Lurasidone

People who have bipolar depression face a 50% lifetime risk of attempting suicide and a 20% risk of death from suicide. Over seven million people in the U.S. are struggling…

Continue Reading Suicidal Bipolar Depression: Clinical Trial Results of NRX-101 Found Superior Safety and Similar Efficacy Compared to Lurasidone